drugset / Trial / NCT07532876
Comparison of Elagolix and OCPs in Reducing Endometriosis Associated Pelvic Pain
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is designed to provide direct evidence on the relative effectiveness and safety of Elagolix versus OCPs, helping physicians make more tailored treatment decisions.
Timeline
- Start
- 2026-05-01
- Primary completion
- 2026-10-01
- Completion
- 2026-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elagolix | Small molecule | 150 mg | — |